Crinetics Q4 2022 Earnings Report
Key Takeaways
Crinetics Pharmaceuticals reported a net loss of $45.0 million for the fourth quarter of 2022, with revenues of $0.7 million. The company's cash, cash equivalents, and investments totaled $334.4 million as of December 31, 2022. They expect the current cash to fund operations through 2024.
Phase 3 PATHFNDR-1 study enrollment complete, topline data expected in 3Q 2023.
Phase 3 PATHFNDR-2 study enrollment ongoing, topline data now expected in 1Q 2024.
Paltusotine's Phase 2 study in carcinoid syndrome on track for data in 2H 2023.
CRN04894's studies in Cushing's disease and congenital adrenal hyperplasia commenced in 1Q 2023.
Crinetics
Crinetics
Forward Guidance
Crinetics expects that current cash, cash equivalents and short-term investments will fund its current operating plan through 2024.